Madrigal Pharmaceuticals
Price & Volume
Stats
See moreOpen | $387.80 |
Previous Close | $391.43 |
Day Range | $374.84-$388.17 |
52W Range | $200.63-$393.76 |
Market Cap | $8.2B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $515.5M |
Revenue Growth (YoY) | 1,353.8% |
Gross Profit (12 Mos) | $496.3M |
Diluted EPS | -$12.65 |
News
See moreYahoo Finance • 4 hours ago
Madrigal's MASH treatment Rezdiffra receives EU approval
Yahoo Finance • 4 hours ago
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Yahoo Finance • yesterday
Madrigal Pharmaceuticals' general counsel sells $479,626 in stock
Yahoo Finance • yesterday
Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.
About
CEO | Mr. William J. Sibold |
CFO | Ms. Mardi C. Dier |
Address | Four Tower Bridge, West Conshohocken, PA, United States, 19428 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 528 |
